Compare Amgen, Inc. (AMGN) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Gold Fields Limited — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Gold Fields Limited trades at $33.87 (market cap $30.43B). The key difference: Amgen, Inc. is far larger — about 6.4× Gold Fields Limited's market cap, and Gold Fields Limited pays the higher dividend (6.79%). Which is the better fit depends on your goals.
| AMGN | GFI | |
|---|---|---|
Market Cap | $196.12B | $30.43B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $61.52 |
52-Week Low | $271.18 | $23.95 |
Enterprise Value | $241.41B | $31.87B |
Dividend Yield | 2.77% | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Gold Fields (GFI) trades at $34.14, up 0.29% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong profitability with a 40.76% net income margin and 52.33% ROE, supported by revenue growth from $5.2B in 2024 to a projected $8.8B in 2025. Recent news highlights operational challenges amid gold price volatility, with Q1 2025 production up 15% but costs rising 13% due to inflation (Seeking Alpha, 2026-06-29).
The outlook is mixed: analyst consensus is a Buy with a $53.13 price target, implying 56% upside, but technical weakness and earnings misses in Q2 and Q4 2025 pose near-term risks. Long-term value hinges on cost control and gold price stability, with debt-to-asset ratio improvements from 25.01% in 2024 to 18.27% in 2025 signaling stronger balance sheet health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
